ClinCalc Pro
Menu
Antimuscarinic — Overactive Bladder Pregnancy: Avoid in pregnancy — limited safety data

Trospium Chloride

Brand names: Regurin, Regurin XL

Adult dose

Dose: 20 mg twice daily (immediate release); 60 mg once daily (XL formulation)
Route: Oral
Frequency: Twice daily (IR) or once daily (XL)
Max: 40 mg/day (IR); 60 mg/day (XL)
Take IR formulation on empty stomach (food reduces absorption by 70%). XL formulation taken in the morning. Preferred antimuscarinic in elderly due to lower CNS penetration

Paediatric dose

Dose: Not applicable N/A/kg
Route: Oral
Frequency: Not applicable
Max: Not applicable
Not licensed in children

Dose adjustments

Renal

Reduce to 20 mg once daily if eGFR under 30

Hepatic

Use with caution in hepatic impairment

Paediatric weight-based calculator

Not licensed in children

Clinical pearls

  • Quaternary ammonium compound — does not cross the blood-brain barrier; significantly lower cognitive adverse effects and dementia risk compared to tertiary amines (oxybutynin, tolterodine, solifenacin) — preferred in elderly patients
  • STOPP v3: tertiary antimuscarinic antimuscarinics are potentially inappropriate in elderly with cognitive impairment; trospium (quaternary) is the exception
  • IR formulation must be taken on an empty stomach — absorption reduced by 70-85% with food; a common reason for treatment failure
  • If antimuscarinic is needed in a patient with dementia or cognitive impairment, trospium is the safest choice due to minimal CNS penetration
  • NICE NG123: Antimuscarinics or mirabegron for OAB — offer patient choice based on individual preferences, comorbidities, and tolerability

Contraindications

  • Urinary retention
  • Gastric retention
  • Uncontrolled narrow-angle glaucoma
  • Myasthenia gravis

Side effects

  • Dry mouth (common)
  • Constipation
  • Blurred vision
  • Tachycardia
  • Urinary retention
  • Cognitive effects (significantly less than other antimuscarinics due to quaternary ammonium structure)

Interactions

  • Other antimuscarinics (additive effects)
  • Metformin, morphine, procainamide (compete for renal tubular secretion — may increase trospium levels)
  • Alcohol (increased risk of somnolence with XL)

Monitoring

  • OAB symptom scores (ICIQ-OAB)
  • Post-void residual (to exclude retention)
  • Cognitive function (less concern than other antimuscarinics)
  • Bowel function

Reference: BNFc; BNF 90; NICE NG123 (Urinary Incontinence and OAB); STOPP/START v3; EAU OAB Guidelines 2024. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.